Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32622830.
- Also identified by DOI 10.1016/j.kint.2020.05.053.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In recent years, a substantial body of experimental and clinical work has been devoted to C3 glomerulopathy and Ig-mediated membranoproliferative glomerulonephritis. Despite the rapid accumulation of data, several uncertainties about these 2 rare forms of nephropathies persist. They concern their pathophysiology, classification, clinical course, relevance of biomarkers and of pathology findings, and assessment of the efficacy of the available therapies. The present review discusses the impact of these uncertainties on the clinical management of patients.
Medical subject headings
- Glomerulonephritis, Membranoproliferative
- Kidney Diseases